CIOMS and ICH initiatives in pharmacovigilance and risk management: Overview and implications

Drug Safety

Volumn 27, Issue 8, 2004, Pages 509-517

  Tsintis, Panos ^a   La Mache, Edith ^a  

^a Europ Agy the Eval of Med Prod   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; NON PRESCRIPTION DRUG;

DATA BASE; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; NON PROFIT ORGANIZATION; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT;

DRUG INDUSTRY; HUMANS; INTERNATIONAL AGENCIES; INTERNATIONAL COOPERATION; RISK ASSESSMENT; RISK MANAGEMENT;

EID: 3042653098     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427080-00004     Document Type: Review

References (20)

1. Burley DM. The rise and fall of thalidomide. Pharm Med 1988; 3: 231-7
2. Fung M, Thornton A, Mybeck K, et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets: 1960 to 1999, Drug Inf J 2001; 35: 293-317
3. Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines, do recent market removals mean there is a problem? JAMA 1999; 281: 1728-34
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998; 279: 1200-5
5. Waller PC, Coulson RA, Wood SM. Regulatory Pharmacovigilance in the United Kingdom; Current Principles and Practice. Pharmacoepidemiol Drug Saf 1996; 5: 363-75
6. The importance of pharmacovigilance. World Health Organisation, 2002
7. Waller PC, Evans JW. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12: 17-29
8. Establishing a European risk-management strategy [online]. Available from URL: http:/heads.medagencies.org/heads/docs/summary.pdf [Accessed 2004 Apr 30]
9. Available from URL: http://www.fda.gov/cder/meeting/riskManageI.htm http://www.fda.gov/OHRMS/DOCKETS/ 98fr/2004d-0188-gd11001.doc [Accessed 2004 May 6]
10. Available from URL: http://www.cioms.ch/frame_current_ programme.htm [Accessed 2004 Apr 30]
11. International Reporting of Adverse Drug Reactions: final report of CIOMS Working Group. Geneva: Council for International Organizations of Medical Sciences, 1990
12. International Reporting of Periodic Drug-Safety Update Summaries: final report of CIOMS Working Group II. Geneva: Council for International Organizations of Medical Sciences, 1992
13. Guidelines for preparing core clinical-safety information on drugs. 2nd ed. Including new proposals for investigator's brochures. Report of CIOMS Working Group III. Geneva: Council for International Organizations of Medical Sciences, 1999
14. Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV. Gerjeva: Council for International Organizations of Medical Sciences, 1998
15. Current challenges in pharmacovigilance: pragmatic approaches report of CIOMS Working Group V. Geneva: Council for International Organizations of Medical Sciences, 2001
16. Available from URL: http://www.meddramsso.com [Accessed 2004 Apr 30]
17. Access via Guidelines E [online]. Available from URL: http://www.ich.org/UrlGrpServer.jser@_TEMPLATE=245 [Accessed 2004 Apr 30]
18. Available from URL: http://eudraVigilance.emea.eu.int [Accessed 2004 Apr 30]
19. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride. Impact of Food and Drug Administration Regulatory Action. JAMA 2000 Dec; 284 (23): 3036-9
20. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with Troglitazone. JAMA 2001 Aug; 286 (7): 831-3